Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBT Margin (2023 - 2025)

CG Oncology filings provide 3 years of EBT Margin readings, the most recent being 1776.74% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 519782.0% to 1776.74% in Q4 2025 year-over-year; TTM through Dec 2025 was 3981.26%, a 374850.0% increase, with the full-year FY2025 number at 3981.26%, up 374850.0% from a year prior.
  • EBT Margin hit 1776.74% in Q4 2025 for CG Oncology, up from 2623.53% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1776.74% in Q4 2025 to a low of 1655100.0% in Q4 2023.
  • Median EBT Margin over the past 3 years was 12005.3% (2024), compared with a mean of 193556.09%.
  • Biggest five-year swings in EBT Margin: soared 164812544bps in 2024 and later plummeted -6306403bps in 2025.
  • CG Oncology's EBT Margin stood at 1655100.0% in 2023, then skyrocketed by 100bps to 6974.56% in 2024, then surged by 75bps to 1776.74% in 2025.
  • The last three reported values for EBT Margin were 1776.74% (Q4 2025), 2623.53% (Q3 2025), and 66263.46% (Q1 2025) per Business Quant data.